Leerink Partners Initiates Coverage On Larimar Therapeutics With Outperform Rating, Announces Price Target of $25
Leerink Partners Initiates Coverage On Larimar Therapeutics With Outperform Rating, Announces Price Target of $25
Leerink Partners以跑赢大盘的评级启动对Larimar Therapeutics的报道，宣布目标股价为25美元
Leerink Partners analyst Joori Park initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Outperform rating and announces Price Target of $25.
Leerink Partners分析师Joori Park以跑赢大盘的评级启动了对Larimar Therapeutics（纳斯达克股票代码：LRMR）的报道，并宣布目标股价为25美元。